COST-EFFECTIVENESS ANALYSIS OF THIRD-LINE PAZOPANIB VERSUS REGORAFENIB FOR METASTATIC OR UNRESECTABLE GASTROINTESTINAL STROMAL TUMORS IN CHINA

被引：0
|
作者：
Rui, M. [1 ]
Wang, Yc [1 ]
Cao, Yd [1 ]
Fei, Z. [1 ]
Li, Hc [1 ]
机构：
[1] China Pharmaceut Univ, Nanjing 32, Peoples R China
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 01期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
POSA117
引用
收藏
页码：S56 / S56
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS ANALYSIS OF THE THIRD-LINE TREATMENT OF REGORAFENIB FOR METASTATIC OR UNRESECTABLE GASTROINTESTINAL STROMAL TUMORS IN CHINA
    Wang, Y.
    Rui, M.
    Cao, Y. D.
    Fei, Z.
    Ma, A. X.
    Li, H. C.
    VALUE IN HEALTH, 2021, 24 : S28 - S28
  • [2] Cost-effectiveness analysis of fruquintinib versus regorafenib as the third-line therapy for metastatic colorectal cancer in China
    Guan, Xin
    Li, Hongchao
    Xiong, Xiaomo
    Peng, Cike
    Wang, Ning
    Ma, Xiao
    Ma, Aixia
    JOURNAL OF MEDICAL ECONOMICS, 2021, 24 (01) : 339 - 344
  • [3] Cost-Effectiveness Analysis of Regorafenib versus Other Third-Line Treatments for Metastatic Colorectal Cancer
    Zhong, Jiayun
    Liu, Yu
    Fu, Qian
    Huang, Dan
    Gong, Wenjun
    Zou, Jian
    CANCER MANAGEMENT AND RESEARCH, 2024, 16 : 593 - 602
  • [4] THE COST-EFFECTIVENESS OF REGORAFENIB IN THE TREATMENT OF METASTATIC/INOPERABLE GASTROINTESTINAL STROMAL TUMORS IN TURKEY
    Deger, C.
    Telli, F.
    Gunaldi, M.
    Keskin, S.
    Saglam, S.
    Ozdemir, O.
    Sar, C.
    Parali, E.
    Erdal, E.
    Sumer, F.
    Ozel, O.
    Asan, S.
    VALUE IN HEALTH, 2015, 18 (07) : A455 - A455
  • [5] COST EFFECTIVENESS OF FRUQUINTINIB VERSUS REGORAFENIB AS THE THIRD-LINE THERAPY FOR PATIENTS WITH METASTATIC COLORECTAL CANCER IN CHINA
    Xin, G.
    Li, H. C.
    Peng, C.
    Wang, N.
    Ma, X.
    Xiong, X. M.
    Ma, A. X.
    VALUE IN HEALTH, 2019, 22 : S83 - S83
  • [6] Cost-effectiveness analysis of fruquintinib for metastatic colorectal cancer third-line treatment in China
    Zhi Peng
    Xingduo Hou
    Yangmu Huang
    Tong Xie
    Xinyang Hua
    BMC Cancer, 20
  • [7] Cost-effectiveness analysis of fruquintinib for metastatic colorectal cancer third-line treatment in China
    Peng, Zhi
    Hou, Xingduo
    Huang, Yangmu
    Xie, Tong
    Hua, Xinyang
    BMC CANCER, 2020, 20 (01)
  • [8] COST-EFFECTIVENESS ANA LYSIS OF REGORAFENIB FOR THIRD-LINE METASTATIC COLORECTAL CANCER (MCRC) COMPARED TO CETUXIMAB PLUS IRINOTECAN IN CHINA
    Liu, J.
    Zhu, S.
    Sun, W.
    Tao, L.
    Xiao, D.
    Xuan, J.
    VALUE IN HEALTH, 2018, 21 : S33 - S33
  • [9] Cost-effectiveness analysis of cetuximab as third-line treatment in metastatic colorectal cancer
    Romeo, M.
    Soler, G.
    Martinez Villacampa, M.
    Laquente, B.
    Lopez Doriga, A.
    Pisa, A.
    Rey, M.
    Santos, C.
    Salazar, R.
    Germa Lluch, J. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [10] Fruquintinib or regorafenib as the third-line treatments for metastatic colorectal cancer based on CONCUR and FRESCO trials: A cost-effectiveness analysis.
    Li, Qiu
    Zhang, Mengxi
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345